The same observations were made in studies of IL-17 is in non-axSpA IBD, with two clinical trials of the IL-17 is secukinumab and brodalumab stopped early due to worsening of IBD symptoms in Crohn’s disease patients [99, 100]. The gene discussed is IL17A; the disease is inflammatory bowel disease.